Finerenone
Back to searchMolecule Structure
Scientific Name
Finerenone
Description of the Drug
Finerenone is a nonsteroidal mineralocorticoid receptor antagonist indicated to lower the risk of eGFR decline, end stage kidney disease, cardiovascular death, heart attack, and hospitalization for heart failure in chronic kidney disease associated with type 2 diabetes.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB16165
http://www.drugbank.ca/drugs/DB16165
Brand Name(s)
Kerendia
Company Owner(s)
Bayer Healthcare Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Mineralocorticoid receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL1994 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL8157011 |
| DrugBank | DB16165 |
| PubChem: Thomson Pharma | 144081174 |
| PubChem | 60150535 |
| Nikkaji | J3.584.878I |
| EPA CompTox Dashboard | DTXSID10146928 |
| ChemicalBook | CB72744895 |
| Guide to Pharmacology | 8678 |
